TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01550367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
Study: NCT02656316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: In this group subjects will receive 20 min of treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In this group subjects will receive 20 min of sham stimulation.
Study: NCT03395015

Intervention type: OTHER
Intervention: VAS scale (from 1 to 10) esthetic assessment of facial 3-D images
Description: The rating process is biphasic: firstly a 3-D model is showed to the raters, who can orientate the vultus, familiarize with the 3-D technology and have a first glance evaluation. Secondly, the judges are asked to rate each of the following patient views: right profile, left profile, frontal, neck hyperextension and hyperflexion views Two weeks after the first assessment, the same judges assessed the same number of pictures, once again in random order.

Intervention type: OTHER
Intervention: VAS scale (from 1 to 10) esthetic assessment of facial 3-D images
Description: The rating process is biphasic: firstly a 3-D model is showed to the raters, who can orientate the vultus, familiarize with the 3-D technology and have a first glance evaluation. Secondly, the judges are asked to rate each of the following patient views: right profile, left profile, frontal, neck hyperextension and hyperflexion views Two weeks after the first assessment, the same judges assessed the same number of pictures, once again in random order.
Study: NCT01198249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide
Description: amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide
Description: amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide
Description: amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide
Description: amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
Study: NCT03495206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-2(Edaravone And Borneol) Sublingual Tablet
Description: Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
Study: NCT03801317

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BC/ egg
Description: 4.3 egg powder + 5.7 g bovine colostrum

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 15 grams corn-soya blend

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multiple micronutrient
Description: multiple micronutrient sprinkle powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multiple micronutrient
Description: multiple micronutrient sprinkle powder
Study: NCT00916695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.
Description: Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.~Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.
Description: Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.~Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique.
Study: NCT00646503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600 mg/day, oral telbivudine for 52 weeks
Study: NCT01367938

Intervention type: DEVICE
Intervention: OMNI Apex Ultracongruent Knee Device
Study: NCT03255044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin administered as well as standard heart failure therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin administered as well as standard heart failure therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: guideline directed therapy
Description: standard heart failure therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: guideline directed therapy
Description: standard heart failure therapy
Study: NCT03187587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: imILT
Description: The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy treatment
Description: The standard chemotherapy treamtment arm recieves only chemotherapy.
Study: NCT04491916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irone sucrose
Description: drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
Study: NCT04621656

Intervention type: COMBINATION_PRODUCT
Intervention: January Mobile Application (Sugar AI)
Description: Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.

Intervention type: COMBINATION_PRODUCT
Intervention: January Mobile Application (Sugar AI)
Description: Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.

Intervention type: COMBINATION_PRODUCT
Intervention: January Mobile Application (Sugar AI)
Description: Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.
Study: NCT01347320

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative MRI
Description: Preoperative staging
Study: NCT02930135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect pulp capping
Description: Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect pulp capping
Description: Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
Study: NCT00909571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506E (modified release tacrolimus)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506E (modified release tacrolimus)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf (tacrolimus)
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf (tacrolimus)
Description: injection
Study: NCT00529217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
Study: NCT03102879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative Endodontic Procedure
Description: Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Root Canal Treatment
Description: Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.
Study: NCT02258425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FEM-CARE
Study: NCT02908217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 Intravenous infusions of placebo every 4 weeks.
Study: NCT02600650

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testosterone boosting supplement
Description: Proprietary formulation of Testosterone boosting supplement administered daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Daily administration of Placebo Comparator
Study: NCT02943473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.
Study: NCT02162173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
Study: NCT01117246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
Study: NCT03434730

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Participants will receive a total dose of 400 cGy on day -2 and day -1 as 2 fractions (200 cGy x 2). Participants receiving total body irradiation (TBI) are treated in a standing position, and the treatment takes about 20 to 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Dilute in D5W or NS to make a 2.5 mg/ ml solution. Infuse slowly over approximately 1-4 hours (intermittent infusion) or 24 hours for continuous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: A 1000 mg dose should be placed in 140 ml of D5W. Administer only with D5W, over at least 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: For participants \< 30kg, dilute with 50mL 0.9% sodium chloride. For participants ≥ 30kg, dilute to 100ml with 0.9% sodium chloride. Administer infusion over 60 minutes with infusion set.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: The single use prefilled syringes contain either 300 mcg or 480 mcg Filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. For the prevention/treatment of chemotherapy induced neutropenia, the dose of filgrastim is standardized per body weight: ≤ 60 kg = 300 mcg daily subcutaneously; \> 60 kg = 480 mcg subcutaneously daily.
Study: NCT03256487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buprenorphine 0.3mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: morphine 0.1 mg/kg IV (max 8mg per dose)
Study: NCT02699411

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: dry needling Travell and Simons

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stability and propioception
Description: Start excursion balance test, WOMAC; ROM, EVA.
Study: NCT03471845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Description: Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
Study: NCT02258425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Study: NCT02863744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanced flap with subepithelial connective tissue graft
Description: * Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~* The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures.
Study: NCT03181893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06823859 low
Description: A humanized immunoglobulin neutralizing antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06823859 high
Description: A humanized immunoglobulin neutralizing antibody
Study: NCT00076206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03230565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patient will be given a continuous infusion of local anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patient will be given a scheduled intermittent bolus of local anesthetic.
Study: NCT02412982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg q12h
Description: Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 30 mg q8h
Description: Patients receive enoxaparin 30 mg every 8 hours.
Study: NCT00715806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open MRI scanner.
Description: Imaging in an Open MRI scanner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed MRI scanner.
Description: Imaging in a short-bore closed MRI scanner.
Study: NCT02938650

Intervention type: DRUG
Group type: OTHER
Intervention: Nitrosomonas eutropha
Description: Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
Study: NCT03078868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Scanner
Description: MRI
Study: NCT02957019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19-IL2 - Ph I
Description: Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19-IL2 at RD - Ph II
Description: Patients will receive L19-IL2 at the RD defined during the Phase I part of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
Study: NCT00065208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Energy therapy - 8 biweekly sessions of 30 minutes

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pretend Reiki
Description: Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Rest / Guided Imagery
Description: 4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
Study: NCT00855335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablet twice daily up to 12 weeks postpartum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablet twice daily up to 12 weeks postpartum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: 200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: One 25 mg tablet once daily up to 12 weeks postpartum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat (FDC)
Description: Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
Study: NCT03163667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CB-839
Description: oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: everolimus
Description: oral tablets
Study: NCT03085290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous serum eye drops
Description: Autologous serum eye drop doses will be 6 times daily in each eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous serum eye drops
Description: Autologous serum eye drop doses will be 6 times daily in each eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic serum eye drops
Description: Allogeneic serum eye drop doses will be 6 times daily in each eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic serum eye drops
Description: Allogeneic serum eye drop doses will be 6 times daily in each eye
Study: NCT01257750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (5mg/ml)
Description: Topical pazopanib, 4 times per day for 3 weeks
Study: NCT02602145

Intervention type: OTHER
Intervention: follow-up CTA
Description: All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.